selegiline has been researched along with alpha-synuclein in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (23.08) | 29.6817 |
| 2010's | 6 (46.15) | 24.3611 |
| 2020's | 4 (30.77) | 2.80 |
| Authors | Studies |
|---|---|
| Ebadi, M; Sharma, SK | 1 |
| Carlson, EC; Ebadi, M; Shavali, S; Swinscoe, JC | 1 |
| Hirohata, M; Ono, K; Yamada, M | 1 |
| Braga, CA; Di Giovanni, S; Foguel, D; Follmer, C; Freitas, MS; Khattar, E; Lashuel, HA; Palhano, FL; Romão, L; Silva, JL | 1 |
| Auinger, P; Cain, KC; Cholerton, B; Ginghina, C; Liu, C; Shi, M; Stewart, T; Zhang, J | 1 |
| Göltl, P; Hafenscher, F; Miklya, I; Pencz, N | 1 |
| Kakish, J; Lee, JS; Tavassoly, O | 1 |
| Becker, S; Eisbach, SE; Fernández, CO; Fonseca-Ornelas, L; Giller, K; Outeiro, TF; Paulat, M; Zweckstetter, M | 1 |
| Chen, NH; Heng, Y; Huang, JY; Mou, Z; Yuan, YH; Zhang, QS | 1 |
| Maruyama, W; Naoi, M; Shamoto-Nagai, M | 2 |
| Arawaka, S; Kato, T; Nakamura, Y; Sasaki, A; Sato, H; Shigekiyo, T; Takahata, K; Tsunekawa, H | 1 |
| Guo, K; Jin, M; Li, L; Liu, D; Luo, N; Rong, H; Wang, J; Zhang, J; Zhang, X; Zhang, Y | 1 |
3 review(s) available for selegiline and alpha-synuclein
| Article | Year |
|---|---|
[The role of alpha-synuclein in Parkinson's disease].
Topics: alpha-Synuclein; Animals; Antiparkinson Agents; Endocytosis; Exocytosis; Humans; Lewy Bodies; Nerve Degeneration; Neuroprotective Agents; Parkinson Disease; Prions; Protein Structure, Secondary; Selegiline | 2014 |
Rasagiline and selegiline modulate mitochondrial homeostasis, intervene apoptosis system and mitigate α-synuclein cytotoxicity in disease-modifying therapy for Parkinson's disease.
Topics: alpha-Synuclein; Animals; Apoptosis; Homeostasis; Humans; Indans; Mitochondria; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline | 2020 |
Neuroprotective Function of Rasagiline and Selegiline, Inhibitors of Type B Monoamine Oxidase, and Role of Monoamine Oxidases in Synucleinopathies.
Topics: alpha-Synuclein; Glial Cell Line-Derived Neurotrophic Factors; Humans; Indans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neurodegenerative Diseases; Neuroprotection; Neuroprotective Agents; Proto-Oncogene Proteins c-bcl-2; Selegiline; Synucleinopathies | 2022 |
1 trial(s) available for selegiline and alpha-synuclein
| Article | Year |
|---|---|
Cerebrospinal fluid α-synuclein predicts cognitive decline in Parkinson disease progression in the DATATOP cohort.
Topics: Adult; Aged; Aged, 80 and over; alpha-Synuclein; alpha-Tocopherol; Antiparkinson Agents; Cognition Disorders; Cohort Studies; Disease Progression; Double-Blind Method; Female; Humans; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Selegiline | 2014 |
9 other study(ies) available for selegiline and alpha-synuclein
| Article | Year |
|---|---|
Metallothionein attenuates 3-morpholinosydnonimine (SIN-1)-induced oxidative stress in dopaminergic neurons.
Topics: alpha-Synuclein; Animals; Apoptosis; Caspase 3; Caspases; Cell Line, Tumor; Corpus Striatum; Deoxyadenosines; Dopamine; Gene Expression Regulation; Humans; Lipid Peroxidation; Metallothionein; Metals; Mice; Mice, Inbred C57BL; Mice, Knockout; Mitochondria; Molsidomine; Nerve Tissue Proteins; Neurons; Neuroprotective Agents; Oxidative Stress; Selegiline; Stem Cells; Synucleins; Transcriptional Activation | 2003 |
1-Benzyl-1,2,3,4-tetrahydroisoquinoline, a Parkinsonism-inducing endogenous toxin, increases alpha-synuclein expression and causes nuclear damage in human dopaminergic cells.
Topics: Adenosine Triphosphate; alpha-Synuclein; Antioxidants; Blotting, Western; Cell Line, Tumor; Cell Nucleus; Coenzymes; Cysteine Proteinase Inhibitors; Dopamine; Dose-Response Relationship, Drug; Drug Interactions; Gene Expression Regulation; Glutathione; Humans; Immunohistochemistry; Microscopy, Electron; Nerve Tissue Proteins; Neuroblastoma; Neuroprotective Agents; Oligopeptides; Reactive Oxygen Species; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Selegiline; Synucleins; Tetrahydroisoquinolines; Time Factors; Ubiquinone | 2004 |
Anti-fibrillogenic and fibril-destabilizing activities of anti-Parkinsonian agents for alpha-synuclein fibrils in vitro.
Topics: alpha-Synuclein; Antiparkinson Agents; Bromocriptine; Dopamine; Dose-Response Relationship, Drug; In Vitro Techniques; Molecular Structure; Neurofibrillary Tangles; Pergolide; Polymers; Selegiline; Trihexyphenidyl | 2007 |
The anti-Parkinsonian drug selegiline delays the nucleation phase of α-synuclein aggregation leading to the formation of nontoxic species.
Topics: alpha-Synuclein; Antiparkinson Agents; Humans; Magnetic Resonance Spectroscopy; Microscopy, Electron; Models, Biological; Protein Denaturation; Selegiline | 2011 |
Rasagiline, a suicide inhibitor of monoamine oxidases, binds reversibly to α-synuclein.
Topics: alpha-Synuclein; Calorimetry; Indans; Methamphetamine; Monoamine Oxidase Inhibitors; Nanopores; Neuroprotective Agents; Protein Binding; Selegiline | 2015 |
Small molecule-mediated stabilization of vesicle-associated helical α-synuclein inhibits pathogenic misfolding and aggregation.
Topics: alpha-Synuclein; Antiparkinson Agents; Humans; Indoles; Parkinson Disease; Protein Aggregation, Pathological; Protein Folding; Protein Stability; Protein Structure, Secondary; Selegiline; Synaptic Vesicles | 2014 |
Reassessment of subacute MPTP-treated mice as animal model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Antiparkinson Agents; Astrocytes; Behavior, Animal; Benserazide; Benzothiazoles; Blood-Brain Barrier; Chromatography, High Pressure Liquid; Corpus Striatum; Disease Models, Animal; Drug Combinations; Levodopa; Male; Mice; Mice, Inbred C57BL; Microscopy, Electron; Parkinsonian Disorders; Pramipexole; Selegiline | 2017 |
Monoamine Oxidase-B Inhibition Facilitates α-Synuclein Secretion
Topics: alpha-Synuclein; Animals; ATP-Binding Cassette Transporters; Cell Death; Cell Line, Tumor; Corpus Striatum; Culture Media, Conditioned; Dopaminergic Neurons; Gene Knockdown Techniques; Genetic Vectors; Humans; Indans; Injections; Lysosomes; Male; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Mutation, Missense; Neuroblastoma; Parkinsonian Disorders; Protein Aggregation, Pathological; Protein Transport; Rats; Rats, Sprague-Dawley; Recombinant Proteins; RNA, Small Interfering; Selegiline; Substantia Nigra | 2021 |
Neuroprotective effect of paeoniflorin in the mouse model of Parkinson's disease through α-synuclein/protein kinase C δ subtype signaling pathway.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Annexin A5; Anti-Inflammatory Agents, Non-Steroidal; Antiparkinson Agents; Apoptosis; Disease Models, Animal; Glucosides; Mice; Microscopy, Electron, Transmission; Monoterpenes; Neurotoxins; Parkinsonian Disorders; Protein Kinase C-delta; Rotarod Performance Test; Selegiline; Substantia Nigra | 2021 |